Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study evaluates the tolerability and safety of a single intravenous infusion of ACZ885. It also explores the efficacy of the compound in central macular edema and visual acuity in patients with wet age-related macular edema.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ACZ885 | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Rates of adverse events and serious adverse events, as well as changes in ophthalmic evaluations, laboratory values, electrocardiograms (ECGs) and vital signs over 6 months, following single intravenous infusion of ACZ885. |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in central macular edema from Baseline up to Month 6 Changes in best-corrected visual acuity from Baseline up to Month 6 |
Not provided
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis EH 001 862 778 8300 | COREC,UK | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bern | Switzerland | |||||
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Belfast, Northern Ireland |
| United Kingdom |
| Bristol | United Kingdom |
| Liverpool | United Kingdom |
| London | United Kingdom |
| Nottingham | United Kingdom |
| Southampton | United Kingdom |
| Wolverhampton | United Kingdom |
| ID | Term |
|---|---|
| C541220 | canakinumab |
Not provided
Not provided
Not provided